Skip to main content

Cost-efficient European adaptations of global health economic models

Experience with model adaptations in Austria, Belgium, France, Germany, Italy, Norway, Netherlands, Spain, Sweden, the UK

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Launch of the national newborn screening for spinal muscular atrophy in Sweden

07 Sep 2023

On August 30, 2023, the National Board of Health and Welfare introduced national screening for spinal muscular atrophy (SMA) in newborns. The following documents were published: a report with recommendations on how the screening should be organized, indicators to follow up on the implementation results, and updated regulations.

SMA test should be included in the newborn screening with the so-called PKU test. The screening test aims to identify children with homozygous deletion in the SMN1 gene and 1–3 copies of the SMN2 gene. Screening will not currently include tests to identify children with four copies of the SMN2 gene.

The National Board estimates that seven children will be detected per year with the screening program. As a result, those affected by the most severe forms of SMA can receive treatment before the onset of symptoms.

See the full details in Swedish here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.